Contraindications for Prasugrel and Ticagrelor
Prasugrel Contraindications
Prasugrel has three absolute contraindications that must be strictly observed: active pathological bleeding, any history of prior stroke or transient ischemic attack (TIA), and hypersensitivity to the drug 1.
Absolute Contraindications:
- Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage)
- Prior stroke or TIA at any time - This is critical because TRITON-TIMI 38 demonstrated a dramatically higher stroke rate with prasugrel (6.5%, including 2.3% intracranial hemorrhage) versus clopidogrel (1.2%) in patients with prior cerebrovascular events 1
- Hypersensitivity/anaphylaxis to prasugrel or any component 1
Special Populations Requiring Dose Adjustment (Not Absolute Contraindications):
- Age ≥75 years: Reduce maintenance dose to 5 mg daily (from standard 10 mg) 2
- Body weight <60 kg: Reduce maintenance dose to 5 mg daily 2
The 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines explicitly state prasugrel should NOT be administered (Class 3 Harm recommendation) in patients with history of stroke or TIA due to worse net clinical outcomes 2.
Ticagrelor Contraindications
Ticagrelor has notably fewer absolute contraindications than prasugrel, with active bleeding and hypersensitivity being the primary concerns 3.
Absolute Contraindications:
- Active pathological bleeding
- Hypersensitivity to ticagrelor or any component
Important Precautions (Not Absolute Contraindications):
- Strong CYP3A4 inhibitors: Combination is contraindicated due to drug-drug interactions 4
- History of asthma/COPD: Use with caution as ticagrelor causes transient dyspnea in 10-15% of patients 2, 5
- Aspirin dose: Must use ≤100 mg daily aspirin with ticagrelor (based on PLATO trial post-hoc analysis showing worse outcomes with higher aspirin doses) 2
Key Clinical Decision Points
When choosing between these agents:
Prior stroke/TIA = absolute contraindication to prasugrel → Use ticagrelor or clopidogrel 2, 1
Age ≥75 years or weight <60 kg → Either use reduced-dose prasugrel (5 mg) with caution OR preferentially use ticagrelor 2
Significant respiratory disease → Favor prasugrel over ticagrelor 5
Medically managed ACS (no PCI) → Prasugrel is NOT recommended; use ticagrelor or clopidogrel 3
Unknown coronary anatomy in NSTE-ACS → Do NOT administer prasugrel upstream 3
Common Pitfalls to Avoid
- Do not assume prior TIA is a "relative" contraindication to prasugrel - it is absolute per FDA labeling and guidelines 1
- Do not use standard-dose prasugrel in elderly or low-weight patients without dose reduction 2
- Do not combine ticagrelor with high-dose aspirin (>100 mg) - this reduces ticagrelor's efficacy 2
- Do not give prasugrel to medically managed ACS patients - it is only indicated for those undergoing PCI 3
Real-world data shows approximately 30-38% of ACS patients have at least one contraindication or special condition requiring attention for prasugrel use, with age ≥75 years being the most common (29-20% prevalence) 6, 7. These patients have higher mortality and benefit from ticagrelor as an alternative 7.